The PARVG Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the PARVG gene in the human Raji B lymphocyte line. This polyclonal format provides a heterogeneous pool of gene-edited cells suitable for studying PARVG loss-of-function. Utilizing CRISPR/Cas9 technology ensures efficient gene disruption for robust experimental models.
The Raji cell line, derived from a Burkitt’s lymphoma patient, is an Epstein-Barr virus (EBV)-positive suspension cell line with mature B cell features, including antibody production and antigen presentation. It serves as a widely used model for B cell biology and B-cell malignancies, offering a consistent background for adhesion and signaling research.
PARVG encodes an actin-binding focal adhesion protein that acts as an adaptor within the integrin-ILK-parvin complex, linking integrin-mediated adhesions to the actin cytoskeleton. Through interaction with integrin-linked kinase (ILK) and PINCH1, PARVG regulates actin dynamics, cell spreading, and migration. Its activity is controlled by upstream signals from integrin engagement, TGF-??, FAK, and Src kinases. Downstream, PARVG modulates Rho GTPases Rac1 and Cdc42 to promote actin polymerization and focal adhesion turnover, alongside other focal adhesion components like paxillin, vinculin, and alpha-actinin.
In Raji B lymphocytes, PARVG knockout enables dissection of focal adhesion signaling pathways critical for adhesion, migration, and survival. This model is valuable for studying how cytoskeletal regulation influences B cell functions and lymphoma biology, including integrin-dependent interactions with the microenvironment. It provides insights into potential mechanisms of B-cell malignancy and cancer metastasis.
Applications include B lymphocyte adhesion and migration assays (transwell migration, adhesion assays), immunofluorescence for focal adhesion markers, Western blotting and RT-qPCR for gene expression analysis, flow cytometry for integrin surface levels, and apoptosis assays under detachment. This polyclonal population is ideal for drug screening targeting the integrin-ILK-parvin axis and for signaling studies in a population context. For further information, please contact Ascent Research.
